<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01319812</url>
  </required_header>
  <id_info>
    <org_study_id>BIOFLEX-I</org_study_id>
    <nct_id>NCT01319812</nct_id>
  </id_info>
  <brief_title>Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents</brief_title>
  <acronym>BIOFLEX-I</acronym>
  <official_title>The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to separately demonstrate the safety and efficacy of
      BIOTRONIK's Astron and Pulsar stents. The Pulsar stent will be used for the treatment of
      femoro-popliteal lesions, located in the native superficial femoral artery (SFA) or proximal
      popliteal artery (PPA), while the Astron stent will be used for the treatment of the common
      or external iliac artery lesions.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness Endpoint for the Pulsar Stent: Primary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>The primary effectiveness endpoint for the Pulsar stent group is the primary patency rate at 12 months post-index procedure. Primary patency is defined as freedom from more than 50% restenosis based on the duplex ultrasound peak systolic velocity ratio, comparing data within the treated segment to the proximal normal segment or based on a clinically-indicated TLR with angiographic evidence of &gt; 50% stenosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Endpoint for the Pulsar Stent: Freedom From Procedure- or Stent-related Major Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>The primary safety endpoint for the Pulsar stent is the freedom from procedure- or stent-related major adverse events at 30 days post-index procedure. The major adverse event rate includes mortality, target lesion revascularization and index limb amputation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Effectiveness Endpoint for the Astron Stent - Percentage of Participants With Major Adverse Events (MAE)</measure>
    <time_frame>12 months</time_frame>
    <description>The primary endpoint for the Astron stent is a composite of the rate of procedure- or stent-related major adverse events at 12 months post-index procedure. The major adverse event rate includes 30-day mortality, along with 12-month rates of target lesion revascularization and index limb amputation. Success was measured against a performance goal of 15%, given a 7.5% expected 12-month MAE rate, with an assumed delta value of 7.5%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Assessment for the Pulsar Stent: Individual Rates of Mortality, TLR, and Index Limb Amputation</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the contribution of the individual rates of mortality, target lesion revascularization (TLR) and index limb amputation at 30 days post-index procedure to the primary safety endpoint for the Pulsar stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-Term Safety Assessment for the Pulsar Stent: Major Adverse Event Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the long-term major adverse event rate of the Pulsar stent. Likewise, the endpoint will evaluate the contribution of the individual rates of 30-day mortality and 12-month target lesion revascularization and index limb amputation rates to this overall, long-term major adverse event rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Integrity Assessment for the Pulsar Stent: Stent Fracture Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the Pulsar stent integrity as measured by x-ray at 12 months post-index procedure. An independent angiographic core laboratory reviewed x-ray imaging for presence or absence of a stent fracture. Fractures were assessed with Grade I indicating a single tine fracture, Grade II indicating multiple tine fracture, Grade III indicating stent fracture(s) with preserved alignment of the components, Grade IV indicating stent fracture(s) with mal-alignment of the components, and Grade V stent fracture(s) in a trans-axial spiral configuration. Generally, fractures of Grade I are least severe, increasing in severity to Grade V.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Assessment for the Astron Stent - Distribution of MAE Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the contribution of the individual rates of 30-day mortality and 12-month target lesion revascularization and index limb amputation rates to the primary endpoint for the Astron stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Assessment for the Astron Stent - Primary Patency Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the primary patency of the Astron stent at 12 months post-index procedure as measured by duplex ultrasound. Primary patency is defined as freedom from more than 50% restenosis based on the duplex ultrasound peak systolic velocity ratio, comparing data within the treated segment to the proximal normal segment or based on a clinically-indicated TLR with angiographic evidence of &gt; 50% stenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Assessment for the Astron and Pulsar Stents - Primary Assisted Patency</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the primary assisted patency rate (freedom from remote Target Vessel Revascularization [TVR]) for the Astron and Pulsar stent at 12 months post-index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Effectiveness Assessment for the Astron and Pulsar Stents - Secondary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluate the secondary patency rate (freedom from bypass and amputation of the target limb) for the Astron and Pulsar stent at 12 months post-index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessments for Subjects With the Astron and Pulsar Stents - Ankle - Brachial Index (ABI) Measurement</measure>
    <time_frame>12 months</time_frame>
    <description>The purpose of this endpoint is to compare the ABI measurements between baseline and 12 months post-index procedure. ABI is the ratio of systolic blood pressure of ankle relative to systolic blood pressure of arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessments for Subjects With the Astron and Pulsar Stents - Six-Minute Walk Test</measure>
    <time_frame>12 months</time_frame>
    <description>The purpose of this endpoint is to compare the distance walked during the 6-minute walk test between baseline and 12 months post-index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire PAD Specific Score</measure>
    <time_frame>12 months</time_frame>
    <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire (WIQ) Peripheral Arterial Disease (PAD) specific score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Walking Distance Score</measure>
    <time_frame>12 months</time_frame>
    <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Walking Distance score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100.. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Walking Speed Score</measure>
    <time_frame>12 months</time_frame>
    <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Walking Speed score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100.. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Stair Climbing Score</measure>
    <time_frame>12 months</time_frame>
    <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Stair Climbing score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Procedural Success for Astron and Pulsar Stent</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the acute procedural success of the Astron and Pulsar stent. Acute procedural success is defined as completion of the assigned procedure, the stented lesion having less than 30% residual stenosis determined by angiography immediately after stent placement and no MAEs before hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate the 30-day clinical success of the procedure. The 30-day clinical success is defined as completion of the assigned procedure, the stented lesion having less than 30% residual stenosis determined by angiography immediately after stent placement and no MAEs within 30 days of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety Assessment for Astron and Pulsar Stent: Adverse Event Rates</measure>
    <time_frame>12 month</time_frame>
    <description>Evaluate the rates of all individual adverse event types that are not included in the primary endpoint analyses for the Astron stent and the Pulsar stent group. Please see the Serious Adverse Events and Other Adverse Events sections for event details.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - 30 Day MAE Rate</measure>
    <time_frame>30 days</time_frame>
    <description>Compare the 30 day MAE rate results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Primary Patency at 12-months</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the primary patency at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Primary Assisted Patency at 12-Months</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the primary assisted patency (freedom from remote TVR) at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Secondary Patency Rate at 12-Months</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the secondary patency (freedom from bypass and amputation of the target limb) at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Acute Procedure Success</measure>
    <time_frame>Acute / Date of Procedure</time_frame>
    <description>Compare the acute procedure success results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - 30-Day Clinical Success</measure>
    <time_frame>30 days</time_frame>
    <description>Compare the 30-day clinical success results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - MAE Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the MAE rate results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Primary Patency at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the primary patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Stent Fracture Rate at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the stent fracture rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Primary Assisted Patency at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the primary assisted patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Secondary Patency Rate at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Compare the secondary patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Acute Procedure Success</measure>
    <time_frame>Acute / Date of Procedure</time_frame>
    <description>Compare the acute procedure success results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - 30-day Clinical Success</measure>
    <time_frame>30 days</time_frame>
    <description>Compare the 30-day clinical success results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">463</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Astron Stent Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants indicated for stenting in iliac atherosclerotic lesions.
Intervention: Device: Astron Stents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulsar Stent Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.
Intervention: Device: Pulsar Stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Astron Stents</intervention_name>
    <description>Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.</description>
    <arm_group_label>Astron Stent Group</arm_group_label>
    <other_name>Astron Stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulsar Stents</intervention_name>
    <description>Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.</description>
    <arm_group_label>Pulsar Stent Group</arm_group_label>
    <other_name>Astron Pulsar Stent</other_name>
    <other_name>Pulsar-18 Stent</other_name>
    <other_name>Pulsar Stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        To support the objectives of this study, the following initial inclusion criteria must be
        met for a subject to be enrolled and considered for the index procedure:

          -  Age ≥ 18 years

          -  Willingness to comply with study follow-up requirements

          -  Candidate for PTA

          -  Life-style limiting claudication or rest pain with an ABI ≤ 0.9 (resting or exercise).
             Thigh brachial index (TBI) may be used / performed if ABI is inadequate.

          -  Written informed consent

        For a subject to receive an investigational stent, the following procedure-related criteria
        must be met:

          -  One de novo, restenotic or occluded lesion representing a femoro-popliteal or iliac
             indication OR Two de novo, restenotic or occluded lesions representing one
             femoro-popliteal indication and one iliac indication on contralateral limbs - (i.e.
             one lesion per limb)

          -  Lesions may be one solid lesion or a series of multiple, smaller lesions to be treated
             as one lesion

          -  Subjects with bilateral, SFA/PPA disease (i.e. one SFA/PPA lesion per limb) are
             eligible for enrollment into the study. The target lesion will be selected at the
             investigator's discretion based on study eligibility criteria. The contralateral
             SFA/PPA intervention may be performed at the time of the index procedure (prior to
             treatment of study lesion); however, the use of an investigational treatment is
             prohibited. If the contralateral SFA/PPA intervention is not performed at the time of
             the index procedure, the intervention must be performed at least 30 days after the
             index procedure. The use of an investigational treatment for the contralateral
             intervention is prohibited.

          -  Subjects with bilateral, iliac disease (i.e. one iliac lesion per limb) are eligible
             for enrollment into the study. The target lesion will be selected at the
             investigator's discretion based on study eligibility criteria. The contralateral iliac
             intervention may be performed at the time of the index procedure; however, the use of
             an investigational treatment is prohibited. If the contralateral iliac intervention is
             not performed at the time of the index procedure, the intervention must be performed
             at least 30 days after the index procedure. The use of an investigational treatment
             for the subsequent contralateral intervention is also prohibited.

          -  Femoro-popliteal lesions must be located at least 1 cm distal to the profunda femoris
             artery and at least 3 cm above the knee joint (radiographic joint space)

          -  Iliac lesions must be located only in either the common or external iliac artery

          -  Lesions must be treatable with a maximum of two stents

          -  Angiographic evidence of ≥ 70% stenosis or occlusion (operator visual assessment)

          -  Lesion length ≤ 190 mm (if de novo or restenotic) or ≤ 100 mm (if occluded)

          -  Target vessel reference diameter: 2.5 to 6 mm (SFA/PPA) or 6 to 9 mm (iliac arteries)
             by visual estimate

          -  Angiographic evidence of patent SFA and PPA (iliac indication) and angiographic
             evidence of at least one distal vessel runoff to the foot (both femoro-popliteal and
             iliac indications). Patent is defined as &lt; 50% stenosis.

          -  For SFA/PPA intervention, a significant stenosis (&gt; 70%) or occlusion of an
             ipsilateral, inflow artery (e.g. aortoiliac, common femoral) must be successfully
             treated (use of investigational treatment prohibited) just prior to treatment of the
             target lesion. Successful treatment is defined as no complications and less than 30%
             residual stenosis following intervention.

        Exclusion Criteria

        To support the objectives of this study, the following initial exclusion criteria must not
        be present for a subject to be enrolled:

          -  Subjects pregnant or planning to become pregnant during the course of the study

          -  Life expectancy of less than one year

          -  Rutherford-Becker category 5 or 6. Subjects with ulcers caused by venous disease may
             be enrolled in the study.

          -  Previously stented lesion(s) in the target vessel

          -  Target lesion(s) received previous treatment within 30 days prior to enrollment

          -  Prior peripheral vascular bypass surgery involving the target limb(s)

          -  Thrombophlebitis or deep vein thrombosis within the past 30 days

          -  Known allergy to nitinol (nickel and/or titanium)

          -  Participation in any other clinical investigational device or drug study. Subjects may
             be concurrently enrolled in a post-market study, as long as the post-market study
             device, drug or protocol does not interfere with the investigational treatment or
             protocol of this study.

          -  Previous stroke or transient ischemic attack within the last three months prior to
             enrollment

          -  Previous coronary or peripheral bypass surgery (non-target limb) within 30 days prior
             to enrollment

          -  Intolerance to contrast agents that cannot be medically managed and/or intolerance to
             anti-platelet, anti-coagulant or thrombolytic medications

          -  Refuses blood transfusions

          -  Any medical condition, that in the opinion of the investigator, poses an unacceptable
             risk for implant of a stent according to the study indications

        For a subject to receive an investigational stent the following procedure-related criteria
        must not be present:

          -  INR ≥ 1.6

          -  Concomitant renal failure with serum creatinine level &gt; 2.5 mg/dL

          -  Unresolved neutropenia (white blood cell count &lt; 3,000 / µL) or thrombocytopenia
             (platelet count &lt; 80,000 / µL) at the time of the index procedure

          -  Unresolved bleeding disorder (INR ≥ 1.6) at the time of the index procedure

          -  Presence of other ipsilateral, arterial lesions distal to the target lesion requiring
             treatment within 30 days of the index procedure (either before or after) or at the
             time of the index procedure

          -  Additional percutaneous interventional procedures (cardiac and/or peripheral) planned
             within 30 days after the index procedure

          -  Presence of a complication following pre-dilation of target lesion

          -  Presence of a target vessel/lesion that is excessively tortuous or calcified or is
             adjacent to an acute thrombus that is unresponsive to anti-thrombotic therapies

          -  Target lesion is located within an aneurysm or associated with an aneurysm in the
             vessel segment either proximal or distal to the target lesion

          -  Target lesion requires the use of cutting balloons, atherectomy or ablative devices

          -  Subjects with less than single vessel runoff to the foot
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Burket, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toledo</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>http://www.jvir.org/article/S1051-0443(16)30257-3/abstract</url>
    <description>Twelve-Month Results of the Nitinol Astron Stent in Iliac Artery Lesions</description>
  </link>
  <reference>
    <citation>Burket MW, Brodmann M, Metzger C, Tan K, Jaff MR. Twelve-Month Results of the Nitinol Astron Stent in Iliac Artery Lesions. J Vasc Interv Radiol. 2016 Nov;27(11):1650-1656.e1. doi: 10.1016/j.jvir.2016.06.008. Epub 2016 Aug 16.</citation>
    <PMID>27542591</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>March 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <results_first_submitted>September 2, 2016</results_first_submitted>
  <results_first_submitted_qc>May 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2017</results_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vascular intervention</keyword>
  <keyword>Endovascular</keyword>
  <keyword>Peripheral stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Astron Stent Group</title>
          <description>Subjects implanted with an Astron stent.</description>
        </group>
        <group group_id="P2">
          <title>Pulsar Stent Group</title>
          <description>Subjects implanted with an Astron Pulsar or Pulsar-18 stent.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="280"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The two arms of the BIOFLEX-I study were distinct with no overlap. Totals present here were automatically generated by the clinicaltrials.gov system. Four participants were enrolled in both the Astron and Pulsar stent groups, as allowed in the study protocol. Therefore any presented totals may not be accurate aggregates of data.</population>
      <group_list>
        <group group_id="B1">
          <title>Astron Stent Group</title>
          <description>Subjects implanted with an Astron stent.</description>
        </group>
        <group group_id="B2">
          <title>Pulsar Stent Group</title>
          <description>Subjects implanted with an Astron Pulsar or Pulsar-18 stent.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
            <count group_id="B2" value="302"/>
            <count group_id="B3" value="463"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="10.1"/>
                    <measurement group_id="B2" value="67.3" spread="10.3"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="424"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoked within last 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never smoked or not within last 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cerebrovascular disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of congestive heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of ischemic heart disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of coronary revasularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal insufficiency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Location</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Common iliac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>External iliac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ostial SFA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal SFA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid SFA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal SFA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal popliteal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Calcification</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Length</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.9" spread="21.3"/>
                    <measurement group_id="B2" value="82.0" spread="46.9"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vessel Diameter</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Pre-deployment Minimum Lumen Diameter (MLD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="1.3"/>
                    <measurement group_id="B2" value="1.0" spread="0.9"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-deployment Minimum Lumen Diameter (MLD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" spread="1.2"/>
                    <measurement group_id="B2" value="4.1" spread="0.7"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reference vessel diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="1.5"/>
                    <measurement group_id="B2" value="5.0" spread="0.9"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distal Vessel Runoff</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Available</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 Vessel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Vessel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Vessel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Vessel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Trans-Atlantic Inter-Society Consensus (TASC II) Type</title>
          <description>TASC II grading is from the Trans-Atlantic Inter-Society Consensus. Type A lesions include a single stenosis &lt;10 cm long or a single occlusion &lt;5cm long; type B lesions include multiple lesions &lt;5 cm, a single lesion &lt;15cm, or a single popliteal stenosis; type C lesions include multiple stenosis or occlusions &gt;15 cm with or without calcification, or a chronic total occlusion &gt;20cm involving the popliteal; type D lesions include chronic total occlusions of the popliteal artery and proximal vessels. Generally, Type D lesions are mores severe than Type A lesions.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="NA">Study arms are independent with no overlap or comparison. A total would not present meaningful information and would be conflated by four subjects who were enrolled in both arms of the study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness Endpoint for the Pulsar Stent: Primary Patency</title>
        <description>The primary effectiveness endpoint for the Pulsar stent group is the primary patency rate at 12 months post-index procedure. Primary patency is defined as freedom from more than 50% restenosis based on the duplex ultrasound peak systolic velocity ratio, comparing data within the treated segment to the proximal normal segment or based on a clinically-indicated TLR with angiographic evidence of &gt; 50% stenosis.</description>
        <time_frame>12 months</time_frame>
        <population>Participants for whom patency could be confirmed at 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness Endpoint for the Pulsar Stent: Primary Patency</title>
          <description>The primary effectiveness endpoint for the Pulsar stent group is the primary patency rate at 12 months post-index procedure. Primary patency is defined as freedom from more than 50% restenosis based on the duplex ultrasound peak systolic velocity ratio, comparing data within the treated segment to the proximal normal segment or based on a clinically-indicated TLR with angiographic evidence of &gt; 50% stenosis.</description>
          <population>Participants for whom patency could be confirmed at 12 months.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" lower_limit="60.8" upper_limit="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Endpoint for the Pulsar Stent: Freedom From Procedure- or Stent-related Major Adverse Events</title>
        <description>The primary safety endpoint for the Pulsar stent is the freedom from procedure- or stent-related major adverse events at 30 days post-index procedure. The major adverse event rate includes mortality, target lesion revascularization and index limb amputation.</description>
        <time_frame>30 days</time_frame>
        <population>All participants implanted with an Astron Pulsar or Pulsar-18 stent.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint for the Pulsar Stent: Freedom From Procedure- or Stent-related Major Adverse Events</title>
          <description>The primary safety endpoint for the Pulsar stent is the freedom from procedure- or stent-related major adverse events at 30 days post-index procedure. The major adverse event rate includes mortality, target lesion revascularization and index limb amputation.</description>
          <population>All participants implanted with an Astron Pulsar or Pulsar-18 stent.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Effectiveness Endpoint for the Astron Stent - Percentage of Participants With Major Adverse Events (MAE)</title>
        <description>The primary endpoint for the Astron stent is a composite of the rate of procedure- or stent-related major adverse events at 12 months post-index procedure. The major adverse event rate includes 30-day mortality, along with 12-month rates of target lesion revascularization and index limb amputation. Success was measured against a performance goal of 15%, given a 7.5% expected 12-month MAE rate, with an assumed delta value of 7.5%.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and either met the 30-day mortality categorization or completed a 12-month evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Effectiveness Endpoint for the Astron Stent - Percentage of Participants With Major Adverse Events (MAE)</title>
          <description>The primary endpoint for the Astron stent is a composite of the rate of procedure- or stent-related major adverse events at 12 months post-index procedure. The major adverse event rate includes 30-day mortality, along with 12-month rates of target lesion revascularization and index limb amputation. Success was measured against a performance goal of 15%, given a 7.5% expected 12-month MAE rate, with an assumed delta value of 7.5%.</description>
          <population>Includes all participants who underwent successful implantation and either met the 30-day mortality categorization or completed a 12-month evaluation.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.4" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Assessment for the Pulsar Stent: Individual Rates of Mortality, TLR, and Index Limb Amputation</title>
        <description>Evaluate the contribution of the individual rates of mortality, target lesion revascularization (TLR) and index limb amputation at 30 days post-index procedure to the primary safety endpoint for the Pulsar stent.</description>
        <time_frame>30 days</time_frame>
        <population>All participants implanted with an Astron Pulsar or Pulsar-18 stent.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety Assessment for the Pulsar Stent: Individual Rates of Mortality, TLR, and Index Limb Amputation</title>
          <description>Evaluate the contribution of the individual rates of mortality, target lesion revascularization (TLR) and index limb amputation at 30 days post-index procedure to the primary safety endpoint for the Pulsar stent.</description>
          <population>All participants implanted with an Astron Pulsar or Pulsar-18 stent.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Freedom from 30 day mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from 30 day TLR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from 30 day index limb amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="98.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-Term Safety Assessment for the Pulsar Stent: Major Adverse Event Rate</title>
        <description>Evaluate the long-term major adverse event rate of the Pulsar stent. Likewise, the endpoint will evaluate the contribution of the individual rates of 30-day mortality and 12-month target lesion revascularization and index limb amputation rates to this overall, long-term major adverse event rate.</description>
        <time_frame>12 months</time_frame>
        <population>Participants who reached at least 395 calendar days post procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-Term Safety Assessment for the Pulsar Stent: Major Adverse Event Rate</title>
          <description>Evaluate the long-term major adverse event rate of the Pulsar stent. Likewise, the endpoint will evaluate the contribution of the individual rates of 30-day mortality and 12-month target lesion revascularization and index limb amputation rates to this overall, long-term major adverse event rate.</description>
          <population>Participants who reached at least 395 calendar days post procedure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-day mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target lesion revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="8.8" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Index limb amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stent Integrity Assessment for the Pulsar Stent: Stent Fracture Rate</title>
        <description>Evaluate the Pulsar stent integrity as measured by x-ray at 12 months post-index procedure. An independent angiographic core laboratory reviewed x-ray imaging for presence or absence of a stent fracture. Fractures were assessed with Grade I indicating a single tine fracture, Grade II indicating multiple tine fracture, Grade III indicating stent fracture(s) with preserved alignment of the components, Grade IV indicating stent fracture(s) with mal-alignment of the components, and Grade V stent fracture(s) in a trans-axial spiral configuration. Generally, fractures of Grade I are least severe, increasing in severity to Grade V.</description>
        <time_frame>12 months</time_frame>
        <population>Participants with 12 month (395 day) diagnostic X-ray available for fracture evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Stent Integrity Assessment for the Pulsar Stent: Stent Fracture Rate</title>
          <description>Evaluate the Pulsar stent integrity as measured by x-ray at 12 months post-index procedure. An independent angiographic core laboratory reviewed x-ray imaging for presence or absence of a stent fracture. Fractures were assessed with Grade I indicating a single tine fracture, Grade II indicating multiple tine fracture, Grade III indicating stent fracture(s) with preserved alignment of the components, Grade IV indicating stent fracture(s) with mal-alignment of the components, and Grade V stent fracture(s) in a trans-axial spiral configuration. Generally, fractures of Grade I are least severe, increasing in severity to Grade V.</description>
          <population>Participants with 12 month (395 day) diagnostic X-ray available for fracture evaluation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall stent fracture at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade I stent fracture at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade II stent fracture at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III stent fracture at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade IV stent fracture at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade V stent fracture at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Assessment for the Astron Stent - Distribution of MAE Rate</title>
        <description>Evaluate the contribution of the individual rates of 30-day mortality and 12-month target lesion revascularization and index limb amputation rates to the primary endpoint for the Astron stent.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and either met the 30-day mortality categorization or completed a 12-month evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety Assessment for the Astron Stent - Distribution of MAE Rate</title>
          <description>Evaluate the contribution of the individual rates of 30-day mortality and 12-month target lesion revascularization and index limb amputation rates to the primary endpoint for the Astron stent.</description>
          <population>Includes all participants who underwent successful implantation and either met the 30-day mortality categorization or completed a 12-month evaluation.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-day mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.0" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Target Lesion Revascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.2" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Index limb amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Effectiveness Assessment for the Astron Stent - Primary Patency Rate</title>
        <description>Evaluate the primary patency of the Astron stent at 12 months post-index procedure as measured by duplex ultrasound. Primary patency is defined as freedom from more than 50% restenosis based on the duplex ultrasound peak systolic velocity ratio, comparing data within the treated segment to the proximal normal segment or based on a clinically-indicated TLR with angiographic evidence of &gt; 50% stenosis.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and had a 12-month evaluable duplex ultrasound assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Effectiveness Assessment for the Astron Stent - Primary Patency Rate</title>
          <description>Evaluate the primary patency of the Astron stent at 12 months post-index procedure as measured by duplex ultrasound. Primary patency is defined as freedom from more than 50% restenosis based on the duplex ultrasound peak systolic velocity ratio, comparing data within the treated segment to the proximal normal segment or based on a clinically-indicated TLR with angiographic evidence of &gt; 50% stenosis.</description>
          <population>Includes all participants who underwent successful implantation and had a 12-month evaluable duplex ultrasound assessment.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="83.3" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Effectiveness Assessment for the Astron and Pulsar Stents - Primary Assisted Patency</title>
        <description>Evaluate the primary assisted patency rate (freedom from remote Target Vessel Revascularization [TVR]) for the Astron and Pulsar stent at 12 months post-index procedure.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Effectiveness Assessment for the Astron and Pulsar Stents - Primary Assisted Patency</title>
          <description>Evaluate the primary assisted patency rate (freedom from remote Target Vessel Revascularization [TVR]) for the Astron and Pulsar stent at 12 months post-index procedure.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="94.1" upper_limit="99.6"/>
                    <measurement group_id="O2" value="98.9" lower_limit="96.8" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Effectiveness Assessment for the Astron and Pulsar Stents - Secondary Patency</title>
        <description>Evaluate the secondary patency rate (freedom from bypass and amputation of the target limb) for the Astron and Pulsar stent at 12 months post-index procedure.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Effectiveness Assessment for the Astron and Pulsar Stents - Secondary Patency</title>
          <description>Evaluate the secondary patency rate (freedom from bypass and amputation of the target limb) for the Astron and Pulsar stent at 12 months post-index procedure.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.2" lower_limit="95.8" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Ankle - Brachial Index (ABI) Measurement</title>
        <description>The purpose of this endpoint is to compare the ABI measurements between baseline and 12 months post-index procedure. ABI is the ratio of systolic blood pressure of ankle relative to systolic blood pressure of arm.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis conducted on paired data. ABI measurements were available for 141 participants from both baseline and the 12-month visit for the Astron stent group. ABI measurements were available for 266 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Ankle - Brachial Index (ABI) Measurement</title>
          <description>The purpose of this endpoint is to compare the ABI measurements between baseline and 12 months post-index procedure. ABI is the ratio of systolic blood pressure of ankle relative to systolic blood pressure of arm.</description>
          <population>Analysis conducted on paired data. ABI measurements were available for 141 participants from both baseline and the 12-month visit for the Astron stent group. ABI measurements were available for 266 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
          <units>Ratio (ABI score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ABI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.15"/>
                    <measurement group_id="O2" value="0.70" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Month Visit ABI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.18"/>
                    <measurement group_id="O2" value="0.91" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABI difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.19"/>
                    <measurement group_id="O2" value="0.22" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Six-Minute Walk Test</title>
        <description>The purpose of this endpoint is to compare the distance walked during the 6-minute walk test between baseline and 12 months post-index procedure.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis conducted on paired data. Six-minute walk test results were available for 131 participants from both baseline and the 12-month visit for the Astron stent group. Six-minute walk test results were available for 247 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Six-Minute Walk Test</title>
          <description>The purpose of this endpoint is to compare the distance walked during the 6-minute walk test between baseline and 12 months post-index procedure.</description>
          <population>Analysis conducted on paired data. Six-minute walk test results were available for 131 participants from both baseline and the 12-month visit for the Astron stent group. Six-minute walk test results were available for 247 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
          <units>Feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Six-minute walk distance at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="868.9" spread="446.5"/>
                    <measurement group_id="O2" value="875.3" spread="379.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Six-minute walk distance at 12-month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1026.4" spread="469.5"/>
                    <measurement group_id="O2" value="1088.9" spread="468.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Six-minute walk distance difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.5" spread="420.6"/>
                    <measurement group_id="O2" value="213.6" spread="412.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire PAD Specific Score</title>
        <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire (WIQ) Peripheral Arterial Disease (PAD) specific score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
        <time_frame>12 months</time_frame>
        <population>Analysis conducted on paired data. WIQ PAD responses were available for 143 participants from both baseline and the 12-month visit for the Astron stent group. WIQ PAD responses were available for 265 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire PAD Specific Score</title>
          <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire (WIQ) Peripheral Arterial Disease (PAD) specific score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
          <population>Analysis conducted on paired data. WIQ PAD responses were available for 143 participants from both baseline and the 12-month visit for the Astron stent group. WIQ PAD responses were available for 265 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
          <units>Units on a scale (WIQ score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WIQ PAD Specific Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="29.0"/>
                    <measurement group_id="O2" value="36.7" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WIQ PAD Specific Score at 12-Month Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.1" spread="29.2"/>
                    <measurement group_id="O2" value="75.8" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WIQ PAD Specific Score Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" spread="36.8"/>
                    <measurement group_id="O2" value="39.1" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Walking Distance Score</title>
        <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Walking Distance score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100.. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
        <time_frame>12 months</time_frame>
        <population>Analysis conducted on paired data. WIQ walking distance scores were available for 144 participants from both baseline and the 12-month visit for the Astron stent group. WIQ walking distance scores were available for 264 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Walking Distance Score</title>
          <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Walking Distance score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100.. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
          <population>Analysis conducted on paired data. WIQ walking distance scores were available for 144 participants from both baseline and the 12-month visit for the Astron stent group. WIQ walking distance scores were available for 264 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
          <units>Units on a scale (WIQ score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WIQ Walking Dist Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="24.2"/>
                    <measurement group_id="O2" value="26.1" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WIQ Walking Dist Score at 12-Month Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" spread="39.5"/>
                    <measurement group_id="O2" value="58.7" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WIQ Walking Dist Score Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="38.0"/>
                    <measurement group_id="O2" value="32.6" spread="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Walking Speed Score</title>
        <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Walking Speed score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100.. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
        <time_frame>12 months</time_frame>
        <population>Analysis conducted on paired data. WIQ walking speed scores were available for 143 participants from both baseline and the 12-month visit for the Astron stent group. WIQ walking speed scores were available for 263 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Walking Speed Score</title>
          <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Walking Speed score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100.. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
          <population>Analysis conducted on paired data. WIQ walking speed scores were available for 143 participants from both baseline and the 12-month visit for the Astron stent group. WIQ walking speed scores were available for 263 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
          <units>Units on a scale (WIQ score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WIQ Walking Speed Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="19.2"/>
                    <measurement group_id="O2" value="25.2" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WIQ Walking Speed Score at 12-Month Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="28.6"/>
                    <measurement group_id="O2" value="43.5" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WIQ Walking Speed Score Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="27.5"/>
                    <measurement group_id="O2" value="18.3" spread="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Stair Climbing Score</title>
        <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Stair Climbing score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
        <time_frame>12 months</time_frame>
        <population>Analysis conducted on paired data. WIQ stair climbing scores were available for 142 participants from both baseline and the 12-month visit for the Astron stent group. WIQ stair climbing scores were available for 255 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Stair Climbing Score</title>
          <description>The purpose of this endpoint is to compare Walking Impairment Questionnaire Stair Climbing score between baseline and 12 months post-index procedure. The WIQ is a subjective questionnaire completed by participants at baseline and the 12 month visit which asks questions about mobility to assess walking impairment. Larger numbers indicate better outcomes, with a minimum score of 0 and a maximum score of 100. Please see the following publication for further information:
Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical Trials for Claudication. Assessment of Exercise Performance, Functional Status, and Clinical Endpoints. Vascular Clinical Trialists. Circulation. 1995;92:614-621</description>
          <population>Analysis conducted on paired data. WIQ stair climbing scores were available for 142 participants from both baseline and the 12-month visit for the Astron stent group. WIQ stair climbing scores were available for 255 participants from both baseline and the 12-month visit for the Pulsar stent group.</population>
          <units>Units on a scale (WIQ score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WIQ Stair Climbing Score at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="27.1"/>
                    <measurement group_id="O2" value="36.8" spread="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WIQ Stair Climbing Score at 12-Month Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="36.8"/>
                    <measurement group_id="O2" value="56.9" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WIQ Stair Climbing Score Difference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="35.6"/>
                    <measurement group_id="O2" value="20.1" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Procedural Success for Astron and Pulsar Stent</title>
        <description>Evaluate the acute procedural success of the Astron and Pulsar stent. Acute procedural success is defined as completion of the assigned procedure, the stented lesion having less than 30% residual stenosis determined by angiography immediately after stent placement and no MAEs before hospital discharge.</description>
        <time_frame>30 days</time_frame>
        <population>Includes all participants who underwent implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Procedural Success for Astron and Pulsar Stent</title>
          <description>Evaluate the acute procedural success of the Astron and Pulsar stent. Acute procedural success is defined as completion of the assigned procedure, the stented lesion having less than 30% residual stenosis determined by angiography immediately after stent placement and no MAEs before hospital discharge.</description>
          <population>Includes all participants who underwent implantation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="90.4" upper_limit="97.8"/>
                    <measurement group_id="O2" value="98.0" lower_limit="95.7" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>Evaluate the 30-day clinical success of the procedure. The 30-day clinical success is defined as completion of the assigned procedure, the stented lesion having less than 30% residual stenosis determined by angiography immediately after stent placement and no MAEs within 30 days of the index procedure.</description>
        <time_frame>30 days</time_frame>
        <population>The Astron stent group includes all participants who underwent implantation. The Pulsar stent group includes all participants who underwent implantation except for one, due to subject death occurring in the first 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>Evaluate the 30-day clinical success of the procedure. The 30-day clinical success is defined as completion of the assigned procedure, the stented lesion having less than 30% residual stenosis determined by angiography immediately after stent placement and no MAEs within 30 days of the index procedure.</description>
          <population>The Astron stent group includes all participants who underwent implantation. The Pulsar stent group includes all participants who underwent implantation except for one, due to subject death occurring in the first 30 days.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="90.4" upper_limit="97.8"/>
                    <measurement group_id="O2" value="97.7" lower_limit="95.3" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Safety Assessment for Astron and Pulsar Stent: Adverse Event Rates</title>
        <description>Evaluate the rates of all individual adverse event types that are not included in the primary endpoint analyses for the Astron stent and the Pulsar stent group. Please see the Serious Adverse Events and Other Adverse Events sections for event details.</description>
        <time_frame>12 month</time_frame>
        <population>Includes all participants who underwent implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Safety Assessment for Astron and Pulsar Stent: Adverse Event Rates</title>
          <description>Evaluate the rates of all individual adverse event types that are not included in the primary endpoint analyses for the Astron stent and the Pulsar stent group. Please see the Serious Adverse Events and Other Adverse Events sections for event details.</description>
          <population>Includes all participants who underwent implantation.</population>
          <units>Participants with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - 30 Day MAE Rate</title>
        <description>Compare the 30 day MAE rate results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
        <time_frame>30 days</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O2">
            <title>Astron Stent Group - Non-occlusive</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
          <group group_id="O3">
            <title>Pulsar Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O4">
            <title>Pulsar Stent Group - Non-occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - 30 Day MAE Rate</title>
          <description>Compare the 30 day MAE rate results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Primary Patency at 12-months</title>
        <description>Compare the primary patency at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and had a 12-month evaluable duplex ultrasound assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O2">
            <title>Astron Stent Group - Non-occlusive</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
          <group group_id="O3">
            <title>Pulsar Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O4">
            <title>Pulsar Stent Group - Non-occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Primary Patency at 12-months</title>
          <description>Compare the primary patency at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and had a 12-month evaluable duplex ultrasound assessment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="90.7"/>
                    <measurement group_id="O3" value="59.8"/>
                    <measurement group_id="O4" value="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Primary Assisted Patency at 12-Months</title>
        <description>Compare the primary assisted patency (freedom from remote TVR) at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O2">
            <title>Astron Stent Group - Non-occlusive</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
          <group group_id="O3">
            <title>Pulsar Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O4">
            <title>Pulsar Stent Group - Non-occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Primary Assisted Patency at 12-Months</title>
          <description>Compare the primary assisted patency (freedom from remote TVR) at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.8"/>
                    <measurement group_id="O3" value="96.4"/>
                    <measurement group_id="O4" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Secondary Patency Rate at 12-Months</title>
        <description>Compare the secondary patency (freedom from bypass and amputation of the target limb) at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O2">
            <title>Astron Stent Group - Non-occlusive</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
          <group group_id="O3">
            <title>Pulsar Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O4">
            <title>Pulsar Stent Group - Non-occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Secondary Patency Rate at 12-Months</title>
          <description>Compare the secondary patency (freedom from bypass and amputation of the target limb) at 12-months results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="99.3"/>
                    <measurement group_id="O3" value="97.6"/>
                    <measurement group_id="O4" value="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Acute Procedure Success</title>
        <description>Compare the acute procedure success results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
        <time_frame>Acute / Date of Procedure</time_frame>
        <population>Includes all participants who underwent implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O2">
            <title>Astron Stent Group - Non-occlusive</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
          <group group_id="O3">
            <title>Pulsar Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O4">
            <title>Pulsar Stent Group - Non-occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Acute Procedure Success</title>
          <description>Compare the acute procedure success results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
          <population>Includes all participants who underwent implantation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.6"/>
                    <measurement group_id="O3" value="97.8"/>
                    <measurement group_id="O4" value="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - 30-Day Clinical Success</title>
        <description>Compare the 30-day clinical success results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
        <time_frame>30 days</time_frame>
        <population>Includes all participants who underwent implantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Astron Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O2">
            <title>Astron Stent Group - Non-occlusive</title>
            <description>Participants indicated for stenting in iliac atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
          <group group_id="O3">
            <title>Pulsar Stent Group - Occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was occlusive (100% stenosis).</description>
          </group>
          <group group_id="O4">
            <title>Pulsar Stent Group - Non-occlusive Lesion</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions where the target lesion was non-occlusive (70% to 99% stenosis).</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - 30-Day Clinical Success</title>
          <description>Compare the 30-day clinical success results between evaluable subjects treated for occlusive lesions (100% stenosis) and evaluable subjects treated for non-occlusive lesions (70% - 99% stenosis) for the Astron stent and the Pulsar stent group.</description>
          <population>Includes all participants who underwent implantation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.6"/>
                    <measurement group_id="O3" value="97.8"/>
                    <measurement group_id="O4" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - MAE Rate</title>
        <description>Compare the MAE rate results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group - Standard Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 20 mm and 140 mm.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group - Long Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 141 mm and 190 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - MAE Rate</title>
          <description>Compare the MAE rate results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Primary Patency at 12 Months</title>
        <description>Compare the primary patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group - Standard Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 20 mm and 140 mm.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group - Long Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 141 mm and 190 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Primary Patency at 12 Months</title>
          <description>Compare the primary patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5"/>
                    <measurement group_id="O2" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Stent Fracture Rate at 12 Months</title>
        <description>Compare the stent fracture rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group - Standard Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 20 mm and 140 mm.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group - Long Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 141 mm and 190 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Stent Fracture Rate at 12 Months</title>
          <description>Compare the stent fracture rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Primary Assisted Patency at 12 Months</title>
        <description>Compare the primary assisted patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group - Standard Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 20 mm and 140 mm.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group - Long Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 141 mm and 190 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Primary Assisted Patency at 12 Months</title>
          <description>Compare the primary assisted patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2"/>
                    <measurement group_id="O2" value="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Secondary Patency Rate at 12 Months</title>
        <description>Compare the secondary patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
        <time_frame>12 months</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group - Standard Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 20 mm and 140 mm.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group - Long Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 141 mm and 190 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Secondary Patency Rate at 12 Months</title>
          <description>Compare the secondary patency rate at 12 months between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8"/>
                    <measurement group_id="O2" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Acute Procedure Success</title>
        <description>Compare the acute procedure success results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
        <time_frame>Acute / Date of Procedure</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group - Standard Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 20 mm and 140 mm.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group - Long Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 141 mm and 190 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Acute Procedure Success</title>
          <description>Compare the acute procedure success results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1"/>
                    <measurement group_id="O2" value="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - 30-day Clinical Success</title>
        <description>Compare the 30-day clinical success results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
        <time_frame>30 days</time_frame>
        <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Pulsar Stent Group - Standard Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 20 mm and 140 mm.</description>
          </group>
          <group group_id="O2">
            <title>Pulsar Stent Group - Long Lesion Length</title>
            <description>Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions with a lesion length between 141 mm and 190 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - 30-day Clinical Success</title>
          <description>Compare the 30-day clinical success results between evaluable subjects treated with standard length lesions (between 20 mm and 140 mm) and evaluable subjects treated for long lesions (between 141 mm and 190 mm) for the Pulsar stent group.</description>
          <population>Includes all participants who underwent successful implantation and were included in the 12-month ITT analysis population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7"/>
                    <measurement group_id="O2" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Enrollment through 12-months post-procedure for Astron group Serious and Non-serious Adverse Events. Enrollment through 12-months post-procedure for Pulsar group serious Adverse Events. All events collected from enrollment through 06 April 2016 for Pulsar group Non-serious Adverse Events.</time_frame>
      <desc>For non-serious adverse events with 0 listed for Astron, there may have been events reported for the category however the number events did not reach the 5% threshold for reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Astron Stent Group</title>
          <description>Subjects indicated for stenting in iliac atherosclerotic lesions.</description>
        </group>
        <group group_id="E2">
          <title>Pulsar Stent Group</title>
          <description>Subjects indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Bleeding requiring treatment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Atrial arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Cardiac catheterization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="161"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Superior mesenteric artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Worsening heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Dilated cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Heart block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Ischemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Medication reaction/toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Patent foramen ovale closure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Valvular heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Worsening cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Worsening diabetic control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding left eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="161"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Nausea and/or vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Gallstone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Gastric bypass surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Gastric ulcer(s)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Traumatic injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Open wounds due to injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>E. coli infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Erysipel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Positive E. faecalis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Purulant drainage from wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Clostridium difficile</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Fungemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Groin wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Infection resulting in amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Ingrown toenail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Inner ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Osteomyelitis resulting in amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Pocket infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Septic shock resulting in amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Lumbar laminectomy and fusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Musculoskeletal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Herniated disc</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Axonal sensible polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Increased serum creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Kidney stone(s)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Profound hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin condition/rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty on left external iliac and SFA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Vessel dissection or perforation during PTA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>ICD device replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Failure to deliver stent to intended site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Vessel dissection or perforation during stenting procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Nausea and/or vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Post-surgical wound discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Thrombosis or occlusion during stenting procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Vessel dissection or perforation during placement of thrombolysis catheter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Vessel dissection prior to stent placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Occlusion of bypass graft left illiopopliteal bypass conduit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Stenosis or occlusion in contralateral extremity/target lesion within stent segment in the SFA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Stenosis or occlusion in target extremity outside of stent segment</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Worsening of claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Right femoral occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Stenosis or occlusion of target lesion within stent segment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E2" events="55" subjects_affected="49" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Acute mesenteric ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Arterial embolization distal to puncture site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Carotid stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Contralateral iliac dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Gangrene resulting in amputation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hematoma - non-index procedure related</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Numbness and/or tingling in lower extremities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Open or non-healing wound/ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Planned carotid stenting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Planned PVI in contralateral extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Stenosis or occlusion in contralateral extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="45" subjects_affected="43" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Subclavian stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Varicose veins</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="161"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="33" subjects_affected="30" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="161"/>
                <counts group_id="E2" events="79" subjects_affected="57" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Leg pain and/or cramping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Numbness and/or tingling in lower extremities</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin condition/rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stenosis or occlusion in contralateral extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="40" subjects_affected="35" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Stenosis or occlusion in target exremity outside of stent segment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Stenosis or occlusion of target lesion within stent segment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E2" events="39" subjects_affected="35" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Culley, Director of Vascular Intervention</name_or_title>
      <organization>BIOTRONIK</organization>
      <phone>503-451-8034</phone>
      <email>amy.culley@biotronik.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

